H.C. Wainwright initiated coverage of Kyverna Therapeutics with a Neutral rating and $8 price target. Kyverna is a clinical stage biotech company focused on the treatment of rheumatic and neurologic diseases using one-time DNA-modified cell therapies, the analyst tells investors in a research note. The firm awaits data demonstrating clinically meaningful, durable responses to become more positive on the opportunity ahead for Kyverna.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Oppenheimer doesn’t understand why Cartesian hit by emerging CAR-T short thesis
- Kyverna Therapeutics participates in a conference call with JPMorgan
- Kyverna Therapeutics’ KYV-101 receives U.S. FDA IND clearance
- Kyverna Therapeutics announces report describing the first use of KYV-101
- After Kyverna data, Oppenheimer says Cartesian ‘can exploit’ CAR-T’s ‘baggage’